Conversely, several studies have shown that RAD51 downregulation in HR-proficient cancer cells can lead to an HR-deficient phenotype and improve the effectiveness of current therapies [29], providing the rationale for current efforts to pharmacologically modulate RAD51 activity [30]. This evidence concerns the gene RAD51 and cancer.